[{"orgOrder":0,"company":"Modulus Therapeutics","sponsor":"Ginkgo Bioworks","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Acquisition","leadProduct":"CAR-T Cell Therapy","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Modulus Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Modulus Therapeutics \/ Ginkgo Bioworks","highestDevelopmentStatusID":"2","companyTruncated":"Modulus Therapeutics \/ Ginkgo Bioworks"}]

Find Clinical Drug Pipeline Developments & Deals by Modulus Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Through the acquisition, Ginkgo will get access to the Modulus cell therapy platform assets, including their chimeric antigen receptor and switch receptor libraries for solid tumors, autoimmune, etc.

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          April 02, 2024

                          Lead Product(s) : CAR-T Cell Therapy

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Sponsor : Ginkgo Bioworks

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank